Xeris Biopharma CFO Steven Pieper sells $47,036 in stock

In a recent development, Xeris Biopharma Holdings, Inc. CFO Steven Pieper sold 5,000 shares of the company's common stock on October 1, 2026, for a total of $47,036. The shares were traded at prices ranging from $9.210 to $9.670, with an average price of $9.4073 per share. After the sale, Mr. Pieper retains 1,351,053 shares of Xeris Biopharma common stock.

The stock has been performing well, with shares currently trading at $10.46, marking a 75% increase over the past six months, based on InvestingPro data. However, the Fair Value analysis indicates that the stock may be overvalued at its current price. Mr. Pieper had initiated a Rule 10b5-1 trading plan, which governs his stock sales, back on August 18, 2025.

For those interested in a more detailed look at Xeris Biopharma's financial situation, the Pro Research Report is available on InvestingPro, providing insights into the company's valuation and overall health. Meanwhile, Xeris Biopharma reported its Q2 2026 earnings, achieving $92.1 million in revenue, surpassing expectations. However, the company reported a loss of $0.18 per share, failing to meet analysts' expectations of a $0.01 profit.

Despite these mixed results, Xeris Biopharma has shown strong commercial momentum, with record sales across its product lineup. Notably, the company announced its XP-8121 candidate, a once-weekly subcutaneous levothyroxine treatment for hypothyroidism, which aims to serve the 3-5 million U.S. patients who do not respond to oral levothyroxine. This candidate has garnered attention at a recent virtual event, with Oppenheimer maintaining an Outperform rating and an $18.00 price target.

These recent events shed light on Xeris Biopharma's ongoing strategies in both clinical and commercial realms.